Antikor Biopharma Ltd

Antikor is a privately-held biotechnology company originally spun-out from Imperial College. We specialise in the discovery and development of small-format Antibody (Fragment) Drug Conjugates, known as FDCs. FDCs are a form of targeted cytotoxic chemotherapy combining the specificity of antibodies with the potency of small-molecule chemotherapy drugs. Specifically, FDCs are smaller than conventional Antibody Drug Conjugates (ADCs) meaning better tumour penetration and more rapid systemic clearance, potentially leading to a higher clinical therapeutic index. Antikor are developing the next-generation of solid tumour therapies, with a major interest in gastro-intestinal cancers

Cancer,antibody,chemotherapy,chemistry,phage display,and antibody fragments

Antikor biopharma ltd operates in the Biotechnology research industry.

Antikor biopharma ltd's revenue is 11m - 100m

Antikor biopharma ltd has 11 - 50 employees.